Neurobo Pharmaceuticals Shares Outstanding vs. Number Of Shares Shorted
| NRBODelisted Stock | USD 2.36 0.01 0.43% |
For Neurobo Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Neurobo Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Neurobo Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Neurobo Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Neurobo Pharmaceuticals over time as well as its relative position and ranking within its peers.
Neurobo |
Neurobo Pharmaceuticals Number Of Shares Shorted vs. Shares Outstanding Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Neurobo Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Neurobo Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Neurobo Pharmaceuticals is regarded fifth in shares outstanding category among its peers. It is rated below average in number of shares shorted category among its peers . The ratio of Shares Outstanding to Number Of Shares Shorted for Neurobo Pharmaceuticals is about 251.45 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Neurobo Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Neurobo Number Of Shares Shorted vs. Shares Outstanding
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Neurobo Pharmaceuticals |
| = | 8.62 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Neurobo Pharmaceuticals |
| = | 34.27 K |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Neurobo Number Of Shares Shorted Comparison
Neurobo Pharmaceuticals is currently under evaluation in number of shares shorted category among its peers.
Neurobo Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Neurobo Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Neurobo Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Neurobo Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Neurobo Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company that develops and commercializes multimodal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts. Neurobo Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 5 people.
Neurobo Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Neurobo Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Neurobo Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Neurobo Pharmaceuticals' important profitability drivers and their relationship over time.
Use Neurobo Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neurobo Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurobo Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Neurobo Pharmaceuticals Pair Trading
Neurobo Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Neurobo Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neurobo Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neurobo Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neurobo Pharmaceuticals to buy it.
The correlation of Neurobo Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurobo Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurobo Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neurobo Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Neurobo Pharmaceuticals position
In addition to having Neurobo Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Precious Metals ETFs Thematic Idea Now
Precious Metals ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Precious Metals ETFs theme has 28 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Precious Metals ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Correlation Analysis. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Neurobo Stock
If you are still planning to invest in Neurobo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neurobo Pharmaceuticals' history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |